Treatment for dry mouth sensation in patients after radiotherapy of head and neck

INTERVENTION: /cytology Clinical Trial Drug Experimental group: 40 patients with oral and oropharyngeal cancer submitted to radiotherapy, with ended therapy for more than 3 months, will use a gel with humectant properties, 5 times a day, passing through the entire mouth. Control group: 40 patients with oral and oropharyngeal cancer submitted to radiotherapy, with ended therapy for more than 3 months, will use a gel without humectant properties. All volunteers will use the drug for 30 days and will be evaluated every 15 days. Fluoroscopy Formularies, Dental as Topic Modalities, Sensorial Other Photography, Dental Procedure/surgery Radiation Salivary Elimination CONDITION: Deglutition Disorders Disturbances of salivary secretion Dysphagia Pathological conditions, signs and symptoms; xerostomia; dysgafia; taste disorders; swallowing disorders; changes in salivary secretion ; Xerostomia ; Dysphagia ; Taste Disorders ; Deglutition Disorders ; Disturbances of salivary secretion Taste Disorders Xerostomia PRIMARY OUTCOME: Is expected reduction of the incidence of candidosis in the gel group with the hydration formula Is expected to improve the perception of xerostomia reported by the patient before the start of the study Positive repercussions are expected regarding the function of swallowing and the possible improvement in taste and smell The Wilcoxon non‐parametric tests with paired Bonferroni and Mann‐Whitney correction will be used to analyze the differences found between groups A and B at all times by analyzing the domains related to quality of life UWQOLQ and perception of xerostomia XI. exact Chi‐square (X2) will be used for comparison between groups in the socio‐demographic domains. Friedman's non‐parametric test will be used to compare the values ??obtained in the non‐stimulated salivary flow and pH. All analyzes adopted a level of significance greater than p greater than 0.05 SECONDARY OUTCOME: Secondary outcomes are not expected INCLUSION CRITERIA: Men; Women; over 18 years old; history of oral cavity neoplasm treated with radiotherapy for more than 3 months and less than 2 years after termination